

Research Article

Cantharidin Inhibits Proliferation of Liver Cancer by Inducing DNA Damage via KDM4A-Dependent Histone H3K36 Demethylation

Chao Wei,1 Xiangui Deng,2 Shudi Gao,3 Xuemei Wan,4 and Jing Chen4

1Infectious Disease Department, Qijiang Hospital of the First Affiliated Hospital of Chongqing Medical University, Chongqing 401420, China
2Infectious Disease Department, Wenlong Hospital of Qijiang, Chongqing 401420, China
3Infectious Disease Department, Taiyuan Hospital of Traditional Chinese Medicine, Taiyuan 030009, Shanxi Province, China
4Infectious Disease Department, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610032, Sichuan Province, China

Correspondence should be addressed to Jing Chen; mdchenjing@sctcm120.net.cn

Received 16 March 2022; Revised 19 May 2022; Accepted 27 May 2022; Published 11 July 2022

Objective. To investigate the effect of cantharidin on DNA damage in hepatocellular carcinoma cells and its possible mechanism.

Methods. Cell proliferation assay and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay were used to analyze the effects of cantharidin on cell proliferation and apoptosis of hepatocellular carcinoma cells. The expression levels of DNA damage markers H2AX and P21 were analyzed by qRT-PCR. The expression of KDM4A and H3K36me3 was observed by western blot. The expression of KDM4A was regulated by siRNA or plasmid transfection. The effect of KDM4A on DNA damage induced by cantharidin in liver cancer was observed after overexpression and addiction of KDM4A.

Results. Cantharidin can significantly inhibit the growth of hepatocellular carcinoma cells and induce apoptosis of hepatocellular carcinoma cells. Cantharidin enhances the chemotherapy sensitivity of liver cancer by targeting the upregulation of KDM4A and the regulation of DNA damage induced by H3K36me3. Overexpression of KDM4A enhances DNA damage induced by cantharidin in HCC. KDM4A silencing attenuated the damage of cantharidin to the DNA of HCC cells.

Conclusion. Cantharidin can inhibit the growth and promote apoptosis of hepatocellular carcinoma cells. Meanwhile, cantharidin can induce DNA damage in HCC cells. Mechanism studies have shown that cantharidin induces DNA damage through the demethylation of KDM4A-dependent histone H3K36.

1. Introduction

Hepatocellular carcinoma (HCC), a solid tumor, is a malignant disease with a high frequency and mortality worldwide [1, 2]. Chemotherapy is the main treatment for advanced solid tumors [3–6].

Histone methylation is an important epigenetic modification [7, 8]. Lysine-specific demethylase 4A (KDM4A) specifically catalyzes the demethylation of histone lysine residues, thereby regulating the chromatin structure and gene transcription [9]. Studies have found that KDM4A is involved in the regulation of cell proliferation, differentiation, development, metabolism, and other important biological processes [10, 11]. Its abnormal function is also closely related to the occurrence and development of tumors and other diseases, becoming an important target for tumor therapy [12]. Histone methylation is one of the important epigenetic modifications, which plays an important role in many biological processes such as transcription activation and suppression, sex chromosome silencing, and DDR. Histone H3/H4 methylation mainly occurs at different leucine K sites (K4, K9, K27, K36, K79, and K20) [13]. The activation or suppression of chromosome transcription is related to methylation states such as monomethylation, demethylation, and trimethylation [14]. Histone methylation can regulate the function of DDR, thus affecting its
tumor barrier role in DNA damage. H3K36me (histone H3 methylation at lysine 36) is the extension of the main influencing gene transcription process [15]. These histone modifications are abundant in the coding regions of transcription-activated genes. Studies on its role in DSB repair also showed that H3K36 methylation plays an important role in the NHEJ repair mode of DNA damage repair (DDR) [15].

Cantharidin can inhibit the protein synthesis of tumor cells, and then affect the synthesis of RNA and DNA and the progress of the cell cycle, promote the apoptosis of tumor cells, and inhibit the proliferation of tumor cells [16, 17]. It has been reported that cantharidin can induce apoptosis of HO-8910PM cells with high metastasis in human ovarian cancer [18, 19]. Cantharidin’s promotion of tumor cell apoptosis is also related to the fact that cantharidin is a protein phosphatase inhibitor [20]. Cantharidin has a strong resistance to tumor cell invasion and metastasis. However, the detailed pharmacological mechanisms need to be further studied. In addition, whether cantharidin can induce DNA damage through KDM4A-dependent histone H3K36 demethylation has not been reported.

2. Methods

2.1. Cell Culture. HepG2 and SMMC-7721 cell lines were purchased from ATCC and cultured in a DMEM containing 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 g/mL). It was placed in a constant temperature incubator containing 5% CO₂ at 37°C.

2.2. Cell Transfection. 1 × 10⁵ SMMC-7721 and HepG2 cells were inoculated in 6-well plates with a 2 ml fresh complete medium. After overnight incubation, the medium was removed and a 2 ml medium containing siRNA KDM4A and a transfection reagent was added. After 24 h, the medium was removed and the 2 ml of fresh complete medium (DMEM + 10% FBS) was added to each well. After 48 h, transfection efficiency and subsequent experiments were tested.

2.3. TUNEL Analysis. The cells were prepared into cell suspension, which was respectively introduced into 6-well plates which had been added to the slides. The glass slide with good cells was immersed in 4% paraformaldehyde and fixed for 25 min. The cell slides were placed in 0.1% TritonX-100 prepared with PBS for 2 min. Treatment groups were mixed with a 50 μl TiT + 450 μl luciferase-labeled dUTP solution (the negative control group was added with 50 μl luciferase-labeled dUTP solution), 50 μl TUNEL reaction mixture was added and incubated at 37°C for 60 min away from the light. Each group was incubated with DAPI to avoid light for 5 min, and the samples were stained with nuclei. The tablets were sealed with a sealing solution, and then, the images were observed and collected under a fluorescence microscope. The number of TUNEL-positive cells was counted by the Image J software.

2.4. qRT-PCR. RNA was extracted and each sample was reverse-transcribed into cDNA according to a 20 μl reaction system; reaction conditions were as follows: 42°C for 60 min and 95°C for 5 min. PCR was performed with cDNA as the template, and the quality of cDNA was checked by agarose gel electrophoresis. Then, according to the instructions of the real-time PCR kit, the reaction conditions were set as follows: 50°C for 2 min and 95°C for 10 min, (95°C, 30 s; 60°C, 30 s) × 40 cycles. The internal reference is GAPDH. Specific primer sequences are shown in Table 1. The expression levels of target genes were analyzed by RT-PCR and fluorescence quantitative PCR.

2.5. Histone Extraction. Cells were collected, followed by 1 ml/10⁵ cells, using Triton extraction buffer (‘TEB: containing 0.5% TritonX-100 (V/V), 2 mmol/L phenylmethylsulfonyl fluoride (PMSF), 1% protease inhibitors, and phosphatase inhibitor in PBS) and the cells were resuspended. Under slow shaking, the cells were lysed on ice for 10 min and centrifuged at 2000 r/min for 10 min at 4°C. The supernatant was removed. The centrifugation was repeated again and the supernatant was discarded. 0.2 mol/L HCl was added and the cells were resuspended according to 1 ml/4 × 10⁵ cells. The histones were extracted at 4°C overnight. The supernatant was centrifuged and collected, that is, the histone extraction liquid.

2.6. Western Blot. Cells were seeded in 6-well plates at 5 × 10⁵ cells/well. After culturing for 24 h, different concentrations of cantharidin were added and incubated for 48 h. The total cell protein was extracted, and the concentration of the protein sample was determined by BCA and then mixed with 5 × protein loading buffer according to a loading amount of 30 μg. It was boiled in water for 5 min to denature it. The samples for SDS-PAGE were taken. The target protein was transferred on the separation gel to the PVDF membrane by all-wet electrophoresis. 5% skimmed milk powder was blocked for 1 h. After complete blocking, the primary antibody (1: 1000) was added and incubated at 4°C overnight. The secondary antibody (1: 1000) was added and incubated at room temperature for 2 h. Chemiluminescence detection of the target band, and observation and analysis of the gel imaging system and photographing were performed. The amount of target protein was calculated by the ratio of the absorbance values of the target protein and the internal reference protein.
2.7. **Cell Proliferation Assay.** Cells in the logarithmic growth phase were seeded at $5 \times 10^3$ cells/well in 96-well plates. 200 μl per well, and drug treatment was added after 24 hours when the cells had grown to a density of about 50%. Cells were collected after 48h for CCK-8 experiments. The blank group, negative control group, and drug-treated group without the cells and only the medium were set up with 3 replicate wells in each group following the instructions of the CCK-8 kit. The absorbance value (A value) at 450nm wavelength of each well was read with a microplate reader.

2.8. **Statistical Analysis.** The above experiments were repeated three times, and the experimental results were expressed as mean ± standard deviation (mean ± standard deviation). SPSS 17.0 software was used for statistical analysis. The t test was used for the comparison between the two groups, the data between multiple groups were analyzed by one-way analysis of variance, and pairwise comparison between the groups was performed by the LSD t test.

3. **Results**

3.1. **Effects of Cantharidin on the Viability and Apoptosis of Hepatoma HepG2 and SMMC-7721 Cells.** The growth of HepG2 and SMMC-7721 cells was significantly inhibited by cantharidin stimulation for 48 h. The growth inhibition rates of HepG2 and SMMC-7721 cells increased with the increase of cantharidin concentration (Figures 1(a) and 1(b)). Apoptosis was further detected by the TUNEL assay. The results showed that the apoptosis rate of SMMC-7721 cells increased after cantharidin treatment (Figures 1(c) and 1(d)).

3.2. **Cantharidin Induces DNA Damage and Enhances Chemotherapy Sensitivity of Liver Cancer.** HepG2 and SMMC-7721 cells were treated with cantharidin (10 μM) for 48 h. After cytoplasmic nucleus isolation, the expression of DNA damage markers H2AX and P21 in the nucleus was detected by qRT-PCR. The results showed that H2AX and P21 expressions increased after cantharidin stimulation (Figures 2(a) and 2(b)). These results indicated that cantharidin treatment could...
increase DNA damage in cells. Subsequently, we conducted cell proliferation experiments to verify whether cantharidin can increase the antitumor effect of HCC chemotherapy drugs. Results showed that the cell viability of HepG2 and SMMC-7721 was significantly decreased in 20\(\mu\)M sorafenib combined with cantharidin (10\(\mu\)M) compared to the group given sorafenib alone (Figures 2(c) and 2(d)).

3.3. Cantharidin Upregulated the Expression of KDM4A.

The expression of KDM4A mRNA in HepG2 and SMMC-7721 hepatoma cell lines treated with cantharidin was detected by qRT-PCR after cytoplasmic nucleus isolation. HepG2 and SMMC-7721 cells were treated with cantharidin (10\(\mu\)M) for 48 h, respectively. (a) Sorafenib (20\(\mu\)M) and cantharidin (10\(\mu\)M) combined treatment significantly decreased the viability of HepG2 cells. (d) The viability of SMMC-7721 cells was significantly decreased after sorafenib (20\(\mu\)M) and cantharidin (10\(\mu\)M) were combined. *\(p<0.05\), **\(p<0.01\).

3.4. Overexpression of KDM4A Enhances DNA Damage Induced by Cantharidin in Liver Cancer.

The expression of KDM4A in HepG2 and SMMC-7721 cells with KDM4A overexpression (KDM4A-OE) was detected by qRT-PCR. Experimental results showed that the expression level of KDM4A was upregulated in the overexpression group (Figure 4(a)). Western blot was used to detect the expression of KDM4A and H3K36me3 in normal and KDM4A-overexpressed liver cancer cells and cantharidin-treated groups. The results showed that compared with the control group, the expression level of KDM4A was upregulated in both
cantharidin stimulation and KDM4A overexpression groups. The expression level of the KDM4A + cantharidin treatment group was the highest. Compared with the control group, both cantharidin stimulation and KDM4A overexpression could inhibit the expression of H3K36me3. Meanwhile, the expression level of H3K36me3 in the treatment group with simultaneous overexpression of KDM4A + cantharidin was the lowest (Figure 4(b)). The expression levels of H2AX and P21 were detected after different treatments, and the DNA damage of HCC cells was analyzed. The results showed that after cantharidin + overexpression KDM4A combined treatment, H2AX and P21 had the highest expression (Figures 4(c) and 4(d)). Cell activity detection experiments also showed that the cell activity was the lowest after cantharidin + KDM4A overexpression combined treatment (Figure 4(e)). These results indicate that overexpression of KDM4A enhances DNA damage induced by cantharidin in liver cancer.

3.5. KDM4A Silencing Can Weaken the Damage of Cantharidin to the DNA of HCC Cells. The mRNA levels of KDM4A in HepG2 and SMMC-7721 cells were detected by qRT-PCR. The results showed that siRNA could significantly reduce the expression level of KDM4A (Figure 5(a)). Western blot results showed that compared with the cantharidin treatment group, siRNA KDM4A + cantharidin treatment decreased the KDM4A expression, while the H3K36me3 expression was upregulated (Figure 5(b)). Results of H2AX and P21 expression detection showed that H2AX and P21 expression levels decreased in the siRNA KDM4A + cantharidin treatment group compared to Figures 5(c) and 5(d). Cell activity detection experiments also showed that compared with the cantharidin treatment group, the cell activity increased after cantharidin + siRNA KDM4A combined treatment (Figure 5(e)). These results suggest that KDM4A silencing can attenuate the damage of cantharidin to the DNA of HCC cells.

4. Discussion

Liver cancer has a very negative impact on people’s health and life, and so far, there is no effective treatment [21, 22]. Changes in the cell’s internal and external environment often lead to DNA molecular damage and structural changes. DNA double-strand break (DSB) is one of the most
serious manifestations of DNA damage [23]. On the other hand, the current treatment of tumors is often carried out by destroying the DNA in tumor cells [24, 25].

As a key epigenetic enzyme regulating gene expression, abnormal activity of KDM4A is associated with the occurrence of a variety of tumors [26]. KDM4A overexpression can significantly block the regulation of miR-526b on cell growth and invasion, thus promoting the growth of gastric cancer cells [27]. Neault et al. [28] found that mir-137 targets KDM4A mRNA and activates p53 in pancreatic cancer cells, inhibiting cell proliferation. In the treatment of pancreatic cancer, fisetin can induce the expression of RFXAP (regulatory factor X-associated protein), which leads to the upregulation of the KDM4A expression and the down-regulation of H3K36 methylation, thus inhibiting the DNA damage repair pathway [29]. KDM4A is the target gene of RFX5 (regulatory factor X-5) in hepatocellular carcinoma cells. The Rfx5-kdm4a pathway promotes the process of the
cell cycle from the G0/G1 phase to the S phase and inhibits apoptosis [30]. Due to the important role of KDM4A in tumor genesis and treatment, the study of KDM4A inhibitors is particularly important. Targeting KDM4A has become a hot topic in the treatment of tumors. The KDM4A inhibitor JIB-04 can restore the level of H3K36me3 and the sensitivity of tumor cells to cytarabine [31]. JIB-04 is a small molecule inhibitor that can destroy the binding between KDM4A and oxygen molecules [32]. In this study, the antitumor effect of cantharidin and its increasing antitumor effect of sorafenib are related to the inhibition of KDM4A. Histone methylation may play an important regulatory role in DNA damage response. The subsequent discovery of histone demethylase proved the reversibility of this modification process. Histone H2AX is a biomarker of DNA double-strand break in vivo [33]. It plays an important role in DNA damage.

**Figure 5**: KDM4A silencing attenuates cantharidin-induced DNA damage in hepatoma cells. (a) KDM4A mRNA levels in the control and KDM4A silenced (siRNA) HepG2 were detected by qRT-PCR. (b) Western blot detection of KDM4A and H3K36me3 expression changes. KDM4Ai-HepG2 cells were treated with cantharidin (10μM) for 48 h. (c) The expression of H2AX was detected after different treatments, and the DNA damage of liver cancer cells was analyzed. KDM4Ai-HepG2 cells were treated with cantharidin (10μM) for 48 h. (d) The expression of p21 was detected after different treatments, and the DNA damage of liver cancer cells was analyzed. Cells were treated with cantharidin (10μM) for 48 h. (e) CCK-8 detection of HepG2 cells with siRNA KDM4A. Cells were treated with cantharidin (10μM) for 48 h. *p < 0.05, **p < 0.01.
signal transduction and the recruitment of repair proteins. H2AX is also closely related to genome stability, cell cycle, and apoptosis [34]. H2AX is closely related to the occurrence and development of tumors [35, 36]. By detecting the changes of DNA damage markers H2AX and P21, the occurrence of DSBs in HCC cells under different time and concentration gradient conditions was observed. The expression levels of H2AX and P21 increased with cantharidin stimulation. This is a manifestation of DNA damage caused by cantharidin.

Due to KDM4A's versatility, this study further investigated the role of the KDM4A gene in DNA damage of tumor cells induced by chemotherapeutic drugs. The effect of KDM4A gene silencing on cantharidin-induced DNA damage in hepatocellular carcinoma cells was observed by transfection of the KDM4A-OE overexpressed plasmid. It was confirmed that the DNA damage of hepatoma cells transfected with the KDM4A-OE interfering plasmid was increased compared with the control cells under the treatment of cantharidin (10 μM). The reason may be that the expression of the KDM4A gene is upregulation; therefore, DNA damage repair is obstructed and the cells cannot repair broken DNA in time, thus promoting DNA damage induced by cantharidin.

This study found that cantharidin can inhibit liver cancer by promoting DNA damage. The promotion of DNA damage is achieved by acting on KDM4A. In this study, we found that cantharidin can regulate epigenetic effects of tumors and then play an antitumor effect. The research on the pharmacological action of antitumor drugs has a reference significance.

5. Conclusion

In conclusion, cantharidin can reduce the survival rate of HCC cells and promote the occurrence of DNA damage. Transfection of the KDM4A overexpressed plasmid can upregulate the expression of KDM4A and promote DNA damage of hepatoma cells induced by cantharidin. In addition, cantharidin induces DNA damage and enhances chemotherapy sensitivity of liver cancer. Mechanism studies suggest that cantharidin induces DNA damage through KDM4A-dependent demethylation of histone H3K36. The results of this study provide a new reference for the combined application of cantharidin with chemotherapy drugs.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] K. A. McGlynn, J. L. Petrick, and H. B. El-Serag, "Epidemiology of hepatocellular carcinoma," Hepatology, vol. 73, no. S1, pp. 4–13, 2021.
[2] J. D. Yang and J. K. Heimbach, "New advances in the diagnosis and management of hepatocellular carcinoma," BMJ, vol. 371, 2020.
[3] M. Ikeda, C. Morizane, M. Ueno, T. Okusaka, H. Ishii, and J. Furuse, "Chemotherapy for hepatocellular carcinoma: current status and future perspectives," Japanese Journal of Clinical Oncology, vol. 48, no. 2, pp. 103–114, 2018.
[4] Y. Sun, W. Ma, Y. Yang et al., "Cancer nanotechnology: enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy," Asian Journal of Pharmaceutical Sciences, vol. 14, no. 6, pp. 581–594, 2019.
[5] W. Zhong, W. Yang, Y. Qin et al., "6-Gingerol stabilized the p-VEGFR2/VE-cadherin/p-catenin/actin complex promotes microvesSEL normalization and suppresses tumor progression," Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 285, 2019.
[6] T. Xiao, W. Zhong, J. Zhao et al., "Polyphyllin I suppresses the formation of vasculogenic mimicry via Twist1/VE-cadherin pathway," Cell Death & Disease, vol. 9, no. 9, p. 906, 2018.
[7] A. Suraweera, K. J. O’Byrne, and D. J. Richard, "Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi," Frontiers in Oncology, vol. 8, p. 92, 2018.
[8] E. M. Michalak, M. L. Burr, A. J. Bannister, and M. A. Dawson, "The roles of DNA, RNA and histone methylation in ageing and cancer," Nature Reviews Molecular Cell Biology, vol. 20, no. 10, pp. 573–589, 2019.
[9] L. Guerra-Calderas, R. González-Barrios, L. A. Herrera, D. Cantú de León, and E. Soto-Reyes, "The role of the histone demethylase KDM4A in cancer," Cancer Genetics, vol. 208, no. 5, pp. 215–224, 2015.
[10] S. Z. Cui, Z. Y. Lei, T. P. Guan et al., "Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy," Cancer Science, vol. 111, no. 5, pp. 1567–1581, 2020.
[11] H. Mu, L. Xiang, S. Li, D. Rao, S. Wang, and K. Yu, "MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A," Journal of Cellular Biochemistry, vol. 120, no. 4, pp. 4987–4997, 2019.
[12] J. Xiong, M. Nie, C. Fu et al., "Hypoxia enhances HIFα transcription activity by upregulating KDM4A and mediating H3K9me3, thus inducing ferroptosis resistance in cervical cancer cells," Stem Cells International, vol. 2022, Article ID 1608806, 16 pages, 2022.
[13] M. Xu, C. Long, X. Chen, C. Huang, S. Chen, and B. Zhu, "Partitioning of histone H3-H4 tetramers during DNA replication–dependent chromatin assembly," Science, vol. 328, no. 5974, pp. 94–98, 2010.
[14] N. J. Francis and D. Sihou, "Heredity of the H3/H4: a binary choice?" Trends in Biochemical Sciences, vol. 46, no. 1, pp. 5–14, 2021.
[15] Y. Zhang, C. M. Shan, J. Wang, K. Bao, L. Tong, and S. Jia, "Molecular basis for the role of oncogenic histone mutations in modulating H3K36 methylation," Scientific Reports, vol. 7, no. 1, Article ID 43906, 2017.
[16] D. Liu and Z. Chen, "The effects of cantharidin and cantharidin derivates on tumour cells," Anti-Cancer Agents in Medicinal Chemistry, vol. 9, no. 4, pp. 392–396, 2009.
[17] R. Rauh, S. Kahl, H. Boehzelt, R. Bauer, B. Kaina, and T. Effert, "Molecular biology of cantharidin in cancer cells," Chinese Medicine, vol. 2, no. 1, pp. 8–9, 2007.
[18] T.-L. Jiang, S. E. Salmon, and R. M. Liu, "Activity of camptothecin, harringtonin, cantharidin and curcumae in the human tumor stem cell assay," European Journal of Cancer and Clinical Oncology, vol. 19, no. 2, pp. 263–270, 1983.
[19] F. Naz, Y. Wu, N. Zhang, Z. Yang, and C. Yu, “Anticancer attributes of cantharidin: involved molecular mechanisms and pathways,” *Molecules*, vol. 25, no. 14, p. 3279, 2020.

[20] L. Chu, I. Norota, K. Ishii, and M. Endoh, “Inhibitory action of the phosphatase inhibitor cantharidin on the endothelin-1-induced and the carbachol-induced negative inotropic effect in the canine ventricular myocardium,” *Journal of Cardiovascular Pharmacology*, vol. 41, pp. S89–S92, 2003.

[21] F. X. Bosch, J. Ribes, M. Díaz, and R. Cléries, “Primary liver cancer: worldwide incidence and trends,” *Gastroenterology*, vol. 127, no. 5, pp. S5–S16, 2004.

[22] D. Anwanwan, S. K. Singh, S. Singh, V. Saikam, and R. Singh, “Challenges in liver cancer and possible treatment approaches,” *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, vol. 1873, no. 1, Article ID 188314, 2020.

[23] P. Samadder, R. Aithal, O. Belan, and L. Krejci, “Cancer TARGETases: DSB repair as a pharmacological target,” *Pharmacology & Therapeutics*, vol. 161, pp. 111–131, 2016.

[24] L. H. Hurley, “DNA and its associated processes as targets for cancer therapy,” *Nature Reviews Cancer*, vol. 2, no. 3, pp. 188–200, 2002.

[25] T. Helleday, E. Petermann, C. Lundin, B. Hodgson, and R. A. Sharma, “DNA repair pathways as targets for cancer therapy,” *Nature Reviews Cancer*, vol. 8, no. 3, pp. 193–204, 2008.

[26] A. Sankar, M. Lerdrup, A. Manaf et al., “KDM4A regulates the maternal-to-zygotic transition by protecting broad H3K4me3 domains from H3K9me3 invasion in oocytes,” *Nature Cell Biology*, vol. 22, no. 4, pp. 380–388, 2020.

[27] L.-H. Chen, L.-P. Wang, and X.-Q. Ma, “Circ_SPECC1 enhances the inhibition of miR-526b on downstream KDM4A/YAP1 pathway to regulate the growth and invasion of gastric cancer cells,” *Biochemical and Biophysical Research Communications*, vol. 517, no. 2, pp. 253–259, 2019.

[28] M. Neault, F. A. Mallette, and S. Richard, “miR-137 modulates a tumor suppressor network-inducing senescence in pancreatic cancer cells,” *Cell Reports*, vol. 14, no. 8, pp. 1966–1978, 2016.

[29] G. Ding, X. Xu, D. Li et al., “Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation,” *Cell Death & Disease*, vol. 11, no. 10, p. 893, 2020.

[30] D. B. Chen, X. W. Xie, Y. J. Zhao et al., “RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A,” *Scientific Reports*, vol. 10, no. 1, Article ID 14538, 2020.

[31] B. G. Mar, S. H. Chu, J. D. Kahn et al., “SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia,” *Blood*, vol. 130, no. 24, pp. 2631–2641, 2017.

[32] B. Cascella, S. G. Lee, S. Singh, J. M. Jez, and L. M. Mirica, “The small molecule JB-04 disrupts O2 binding in the Fe-dependent histone demethylase KDM4A/ JMJD2A,” *Chemical Communications*, vol. 53, no. 13, pp. 2174–2177, 2017.

[33] F. Naz, Y. Wu, N. Zhang, Z. Yang, and C. Yu, “Anticancer attributes of cantharidin: involved molecular mechanisms and pathways,” *Molecules*, vol. 25, no. 14, p. 3279, 2020.

[34] L. Chu, I. Norota, K. Ishii, and M. Endoh, “Inhibitory action of the phosphatase inhibitor cantharidin on the endothelin-1-induced and the carbachol-induced negative inotropic effect in the canine ventricular myocardium,” *Journal of Cardiovascular Pharmacology*, vol. 41, pp. S89–S92, 2003.

[35] F. X. Bosch, J. Ribes, M. Díaz, and R. Cléries, “Primary liver cancer: worldwide incidence and trends,” *Gastroenterology*, vol. 127, no. 5, pp. S5–S16, 2004.

[36] D. Anwanwan, S. K. Singh, S. Singh, V. Saikam, and R. Singh, "Challenges in liver cancer and possible treatment approaches," *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, vol. 1873, no. 1, Article ID 188314, 2020.